California
Biotech Insights

Biotech Market Update

Dynavax acquired by Sanofi, Ultragenyx late-stage failure, Crinetics posts strong sales

January 6, 2026

M&A, Deals, Partnerships: Dynavax Technologies (SF) to Be Acquired by Sanofi for $2.2B Cash Sanofi will buy Dynavax for $2.2 billion in cash ($15.50/share) to add Dynavax’s adult hepatitis B vaccine Heplisav-B (a 2-dose series over 1 month vs. the typical 3 doses over 6 months); Heplisav-B generated $90M in Q3 2025 revenue and Dynavax […]

Biotech Market Update

Ambros launches with $125M, Clavis forms $7.25B collaboration with Fosun, BioMarin acquires Amicus

December 23, 2025

Recent Funding: Aeovian Pharmaceuticals (SF) Raises $55M to Advance Selective mTORC1 Therapy for TSC-Related Epilepsy Aeovian secured $55M to complete a Phase 2 trial of AV078, a brain-penetrant, selective mTORC1 inhibitor designed to reduce seizures in tuberous sclerosis complex (TSC), aiming for improved efficacy and fewer side effects than older drugs like rapamycin and everolimus. […]

Biotech Leader Spotlight

Cyril De Colle, Cofounder & CSO at Neurogastrx

December 18, 2025

Cyril De Colle is the Co-founder & Chief Scientific Officer at Neurogastrx, a clinical-stage pharmaceutical company developing products for the treatment of gastrointestinal disorders. Cyril has more than 20 years of drug development experience, having led multiple programs from IND submission to late-stage clinical development. Before Neurogastrx, Cyril led the division at Kinemed responsible for advising global and venture-backed pharmaceutical companies on neuroscience drug development programs. Prior to Kinemed, he led clinical development programs targeting neurological disorders at Jazz Pharmaceuticals and served as a senior research scientist at Amgen and Roche Pharmaceuticals. These experiences led him to explore the role of the enteric nervous system in GI conditions, such as gastroparesis, the focus of Neurogastrx’s NG-101 development program. Cyril has a M.S. in Pharmacology and a PhD in Neuroscience from the University of Montpellier in France.

Biotech Market Update

Chai Discovery raises $130M Series B, Dren Bio lands $100M Sanofi deal, Arthrosi acquired by Sobi

December 16, 2025

Recent Funding: Link Cell Therapies (SF) Launches with $60M to Advance Next-Gen CAR-T for Solid Tumors The Stanford spinout raised $60M in Series A led by J&J’s venture arm, with backing from Samsara BioCapital and Sheatree Capital, plus Bristol Myers Squibb and Kyowa Kirin, among others – to develop logic-gated CAR-T therapies that selectively attack […]

Biotech Leader Spotlight

Gary Li, Chief Strategy / Scientific Officer, Venture Advisor

December 11, 2025

Gary Li has over 20 years of multi-modality drug discovery, translational, and early development experience at both the strategic and operational levels. He is currently the Chief Strategy Officer for AdvanCell, fractional CSO for TippingPoint Biosciences, and advisor for multiple venture capital firms. Previously Gary was a member of RayzeBio’s and SVP, leading Discovery Biology, Translational Medicine, and Portfolio Strategy. He spearheaded the effort to establish a rich portfolio from novel targets to clinical assets. In addition, he played a key role in company building, fundraising, licensing, and scientific communication. Before joining RayzeBio, Dr. Li was SVP, Translational Medicine at BridgeBio, VP of Oncology Research at Ignyta, and held various scientific positions with increasing responsibilities at Pfizer and Johnson & Johnson, contributing to target ID/validation, drug discovery and multiple drug approvals. Gary is an inventor on multiple patents, has published 55 peer-reviewed articles, and delivered over 110 invited talks and meeting presentations.

Biotech Market Update

Immix raises $100M, Mirum acquires Bluejay, FDA moves to phase out primate testing

December 9, 2025

Recent Funding: Immix Biopharma (LA) Raises $100M to Advance CAR-T Therapy for AL Amyloidosis Immix Biopharma priced a $100 million public offering to fund development of NXC-201, its BCMA-targeted CAR-T therapy for relapsed and refractory AL amyloidosis. The company expects the proceeds, along with grant support, to extend its runway into mid-2027 as it advances […]

California Biotech Insights

California
Biotech Insights